Pasteurized Akkermansia muciniphila,
does it really help with Weight loss and prevention of weight regain after loss?
research showsPasteurized A. muciniphila MucT is rated C because a 2026 randomized trial found less weight regain after prior loss. Ninety participants first lost at least 8% of body weight during an eight-week low-energy diet and then received the study product or placebo for 24 weeks; regain was 1.2 kg versus 3.2 kg. The evidence concerns one proprietary strain and company-supplied, company-funded product, while the weight difference in the 2019 exploratory study of 32 completers was not statistically significant. It cannot be generalized to live organisms, other strains, generic probiotics, or all retail products.
ads claimClaims that one gut-bacteria pill causes weight loss, replaces a GLP-1 drug, or that any Akkermansia product prevents regain exceed the evidence. Most loss in the latest positive study occurred first during the roughly 800-kcal low-energy-diet phase, and the tested organism was the specific pasteurized MucT product.
Useful facts when choosing a product
- No South Korean public functional-ingredient record confirming weight-loss or weight-regain functionality for pasteurized A. muciniphila was identified. Domestic sale or direct-import labeling does not equal recognized clinical efficacy.
- The 2019 human study used pasteurized MucT at 10^10 cells/day for 12 weeks. The 2026 maintenance-trial abstract specifies daily dosing but does not provide an exact cell-equivalent dose, so no unsupported conversion is given here.
- A pasteurized product is not measured in the same way as a live probiotic CFU count, and labels may use cell count or TFU. Live A. muciniphila, other strains, and mixed probiotics are not interchangeable with the MucT evidence.
- EFSA judged a specific pasteurized ingredient safe for adults at up to 3.4 x 10^10 cells/day, but this was a safety assessment, not efficacy recognition. Long-term human data and evidence in vulnerable populations such as immunocompromised people remain limited.
What the research actually shows
The 2019 Depommier double-blind exploratory study enrolled 40 insulin-resistant adults with overweight or obesity and 32 completed 12 weeks of live organisms, pasteurized organisms at 10^10 cells/day, or placebo. Some metabolic markers improved with the pasteurized product, but the placebo-adjusted body-weight difference of -2.27 kg had P=0.091. In the 2026 Mount trial, 90 participants first lost at least 8% during an eight-week low-energy diet and then received MucT or placebo for 24 weeks. Primary-outcome weight regain was 1.2 plus or minus 0.7 kg versus 3.2 plus or minus 0.4 kg. Durability beyond 24 weeks, independent replication, and equivalence of other pasteurized strains or live products remain unknown.
Why this is classified as C (49)
A positive randomized trial using a direct body-weight primary outcome rules out D or unknown, but the proprietary product, company funding, selection through prior low-energy-diet success, 24-week duration, and lack of independent replication require the manufacturer and single-product cap of C with 49 points.
Counterpoint. A 24-week maintenance benefit is promising in adults with overweight or obesity who successfully lost weight, but independent replication and long-term follow-up are needed before treating it as a general weight-loss or universal anti-regain product.
Rejudgment record. New verdict — The assessment evaluated direct weight outcomes in the 2019 exploratory study and 2026 maintenance trial while separating prior diet-induced loss, proprietary strain and company funding, and live, pasteurized, and retail-product differences.
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Weight loss caused directly by pasteurized MucT | C | The placebo-adjusted weight difference in the 2019 exploratory trial was nonsignificant at P=0.091, and initial loss in the 2026 trial was induced by a low-energy diet, leaving a direct weight-loss effect unconfirmed. |
| Reduction of weight regain for 24 weeks after successful loss | C | The direct primary outcome was positive in the 2026 trial, but the evidence concerns one proprietary company-funded product in a selected population without independent replication. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Randomized double-blind placebo-controlled proof-of-concept trial | 32 | WELBIO and other support with reported A-Mansia-related interests and patents | Safety, insulin sensitivity, lipids, inflammation, body composition, and weight | Pasteurized organisms at 10^10 cells/day for 12 weeks improved some metabolic markers; placebo-adjusted weight difference was -2.27 kg with P=0.091 and was nonsignificant. | Exploratory; surrogate-marker centered |
| Study 2 | Controlled randomized placebo-controlled weight-maintenance trial | 90 | The Akkermansia Company supplied intervention and placebo and funded the study; company officers, employees, advisers, and patent interests were reported | Primary outcome of body-weight change during 24-week maintenance | After at least 8% loss on an eight-week low-energy diet, regain was 1.2 plus or minus 0.7 kg with MucT versus 3.2 plus or minus 0.4 kg with placebo, P=0.012. | Key positive; company concentrated |
| Study 3 | Novel-food safety scientific opinion | EU regulatory assessment including applicant data | Safe intake of a specified pasteurized ingredient | Concluded that up to 3.4 x 10^10 cells/day was safe for adults; weight-loss efficacy was not assessed. | Safety only |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] Pasteurized Akkermansia muciniphila x weight loss and prevention of regain — Evidence Grade C·49. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/weight/pasteurized-akkermansia-weight-loss-maintenance/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.